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Summary In a comparative study of pre- and postmenopausal women with benign and malignant breast
disease, a number of differences were observed in circulating plasma prolactin and lipid concentrations.
Plasma lipids, phospholipids, triglycerides, cholesterol and free fatty acids were all higher in blood obtained
from breast cancer patients prior to surgery. HDL-Cholesterol levels were significantly lower in these patients.
These differences remained when the patient groups were sub-divided according to menopausal status. Plasma
prolactin concentrations were also found to be higher in cancer compared with non-cancer patients, this effect
being more marked in premenopausal than in postmenopausal patients. Premenopausal patients with invasive
or poorly differentiated disease had significantly higher prolactin levels than those with non-invasive disease.
No correlations were found between plasma prolactin and any of the lipid fractions.
Many factors have been implicated in the aetiology
of human breast carcinoma. In particular menses,
marital status and parity are significant (Moore,
1983). These factors are thought to operate through
differences in hormonal status associated with
pregnancy, menarche and the menopause. Studies
in animal model systems and human subjects
support a role 'for both prolactin (PRL) and
oestrogens (Pearson, 1978; Meites, 1972; Yanai &
Nagasawa, 1971) in the initiation and development
of mammary tumours.
The other major risk factor identified for breast
cancer is diet; epidemiological evidence (Lea, 1966;
Doll et al., 1970; Carroll & Khor, 1975) and animal
studies (Carroll, 1975; Cave et al., 1979; Chan &
Dao, 1981) support the proposition that increased
dietary fat intake is positively associated with breast
risk. Since feeding high fat diets causes elevation of
plasma prolactin concentrations in rodents (Chan &
Cohen, 1974) and man (Hill et al., 1980) the
suggestion has been made that tumourigenic effects
of high fat diets are mediated through the actions
of PRL. Such a proposition is supported by the
observation in animals, that hypophysectomy
abolishes the tumourigenic effects of high fat diets
(Chan & Cohen, 1974).
Although there is strong circumstantial evidence
for an involvement of PRL in human breast cancer,
evidence from studies in patients themselves, has
produced conflicting reports. Thus, elevated PRL
levels have been reported in certain groups such as
women with late first pregnancies (Hill et al., 1976)
and high risk families (Henderson, et al., 1975;
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Kwa & Wang, 1977; Levin & Malarkey, 1981).
Others have found no evidence for higher PRL
levels in these groups (Fishman et al., 1978). In
patients suffering from breast cancer, elevated levels
of the hormone have been observed at early, and
late stages of the disease.(Tarquini et al., 1978;
Rolandi et al., 1974). Other workers report no
elevation in basal PRL levels but elevated nocturnal
PRL in premenopausal breast cancer patients
(Malarkey et al., 1977) and in response to thyroid
releasing hormone (TRH) administration (Ohgo et
al., 1976). Despite these observations several reports
suggest PRL levels are normal in women with
mammary cancer (Sheth et al., 1975; Boyns et al.,
1973; Cole et al., 1977) and in one study lower
nocturnal PRL levels were observed in post-
menopausal cancer patients (Malarkey et al., 1977).
In view of the considerable evidence for an inter-
active effect of dietary fat and prolactin in the
promotion of mammary tumourigenesis in animals,
further clarification of the role of this hormone in
the aetiology of human breast cancers in relation to
dietary fat is required. Although dietary histories
have been obtained from patients with breast
cancer, such studies are extremely costly and time
consuming and do not yield accurate, quantifiable
results. Studies carried out to date have produced
conflicting evidence with regard to dietary fat
intakes in breast cancer patients (Miller et al., 1978;
Graham et al., 1982). Since plasma lipid levels have
been shown to reflect dietary lipid intakes and
elevated lipid levels have been reported in breast
cancer patients, a study of plasma lipid and PRL
levels might provide useful information on the
relationship between dietary fat, plasma lipids and
PRL levels.
In the present study, plasma prolactin and lipid
concentrations were determined in patients
undergoing surgery for breast disease. Blood
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samples were obtained in all patients pre-
operatively after an overnight fast. Patients
diagnosed with breast cancer at surgery, were
allocated into pre- and postmenopausal groups and
appropriate age-matched control subjects were
selected from patients found to have benign breast
disease.
Patients and methods
A total of ninety-eight patients have been studied.
Forty-eight patients had malignant tumours at an
early stage limited to the breast and regional lymph
nodes, and fifty patients had benign breast disease.
Patients were divided into these groups following
histopathological examination of tissue removed at
surgery. The patients were further divided
according to menopausal status by reference to
their case histories. Patients were classified as
postmenopausal if two years had elapsed since their
last menses. There were twenty-eight pre-
menopausal cancer patients with a mean age of
44+ 1.1 years and a mean body weight of
57.8+ 1 kg, and twenty postmenopausal cancer
patients with a mean age of 59+ 1.4 years and a
mean body weight of 65.3+3.0kg. The non-
Table I Description of cancer patients and non-cancer
control patients
Pre- Post-
All meno- meno-
Description patients pausal pausal
Cancerpatients: Total 48 28 20
In situ duct carcinoma 5 2 3
Invasive duct carcinoma 21 10 11
Adenocarcinoma well
differentiated 16 11 5
Adenocarcinoma poorly
differentiated 2 2
Invasive lobular carcinoma 1 1
Well differentiated tubular
carcinoma 3 2 1
Non-cancerpatients: Total 50 25 25
Fibroadenoma 22 13 9
Duct papilloma 7 3 4
Interlobular sclerosis 2 2
Duct cyst 5 1 4
Benign mammary displasia 3 2 1
Chronic inflammatory cell
inflammation 1 1
Perilobular fibrosis 1 1
Microcystic disease 1 1
Lobular hyperplasia 1 1
Lipoma 5 5
Pamiculitus 1 1
Breast scar lump 1 -
cancerous group was sub-divided into a pre-
menopausal sub-group of 25 patients with a mean
age of 38+2.2 years and a mean body weight of
59+ 1.6kg, and a postmenopausal sub-group of
twenty-five patients with a mean age of 61+1.6
years and a mean body weight of 60.3+2.6kg. As
one group, the mean age of the cancer patients was
52+2 years and the mean body weight 62+2kg.
The histopathological features of the breast cancer
and benign groups are shown in Table I.
As far as could be ascertained, no patient was
receiving phenothiazines, L-Dopa, monoamine
oxidase inhibitors, or other drugs known to affect
the secretion of prolactin.
Blood samples were taken from all patients on
the day before surgery and after a fast of at least
14h. Samples were drawn into lithium heparinized
tubes and immediately chilled on ice. The samples
were centrifuged within 2h of collection and the
plasma stored at -40°C until analysed.
Plasma levels of total phospholipids (Naito,
1975), cholesterol (Rudel & Morris, 1973),
triglycerides (Gottfried & Rosenberg, 1973) and
HDL (Allen et al., 1979) were determined.
Diagnostic reagents were used to quantitate total
lipids (Zoellner & Kirsche, 1962) and free fatty
acids (Duncombe, 1964). In order to minimise
interassay variation, analyses were carried out in
batches with equal numbers of samples from cancer
and non-cancer patients in each batch.
Human prolactin was determined by a
heterologous double antibody radioimmunoassay in
the Radioimmunoassay Unit at St. Luke's Hospital,
Guildford. Ampoules of reference preparation were
obtained from the North East Thames R.I.A. Unit,
St. Bartholomew's Hospital and used as standards.
Rabbit anti-prolactin serum (Batch R51/6/12) was
obtained from the Guildhay Company. Iodinated
prolactin was supplied by the North East Thames
RIA Unit, St. Bartholomew's Hospital. Antiserum
to rabbit globulins raised in the donkey (Batch
HP/D/41/14C) was obtained from Guildhay.
Internal quality control specimens (low, medium
and high) were included at intervals in each assay,
as well as several carry-over specimens from
previous assays.
Differences between groups were initially
analysed using analysis of variance and any
differences found tested for significance using
students unpaired 't' tests.
Results
Postmenopausal patients were significantly heavier
than premenopausal patients (P<0.05) but there
was no significant difference in body weight
between cancer and non-cancer patients. There wasLIPIDS, PROLACTIN AND BREAST CANCER 441
Table II Plasma lipids in cancerous and non-cancerous
patients with breast disease (Number of patients shown in
parenthesis). Values are means+s.e.
Cancer (48) Non-cancer (50)
Age 52+2 50+2
Weight 62+2 60+2
Total lipids
mglOOm1 -1 1235+62 905+25a
Total phospholipids
mglOOmlP1 350+ 13 290+lla
Triglycerides mg 100ml 174+5 148+lOa
Total cholesterol
mglOOml-1 288+ 14 230+9a
HDL-cholesterol
mglOOmlP1 51+3 66+4a
HDL L-cholesterol
Total cholesterol ratio 19+1 30+2a
Free fatty acids
(mmol11) 1.10+0.04 0.68+0.002a
aValues significantly different from
shown P<0.001.
non-cancer are
no significant difference in age between post-
menopausal cancer and non-cancer patients, but
premenopausal cancer patients were slightly older
than non-cancer patients (P<0.05). This difference
was due to the inclusion of four patients between
the ages of 20 and 30 in the non-cancer group.
When results were analysed with and without
values from these patients, it was found that their
inclusion had no effect on mean values for plasma
lipid or prolactin concentrations and no influence
on any differences between cancer and non-cancer
groups or pre- and postmenopausal groups. For
this reason values for these patients have been
included in all the tables and in all statistical
analyses. Table II shows that the plasma lipid
concentrations were higher in cancer than in non-
cancer patients (P<0.001 in all cases) with the
exception of HDL-cholesterol which was lower in
cancer than in non-cancer patients (P<0.001). This,
together with the high level of total cholesterol,
resulted in a lower HDL-cholesterol: Total
cholesterol ratio (P<0.001) Table III shows the
results from Table II with cancer and non-cancer
patients divided into pre- and postmenopausal
groups. In postmenopausal cancer patients all
plasma lipid concentrations were higher than in
non-cancer patients (P<0.001 in all cases), except
HDL-cholesterol levels which were significantly
lower (P<0.001). Similar results were obtained on
comparison of premenopausal cancer and non-
cancer patients although values for total phospho-
lipids were similar (P<0.1) in these groups of
patients. Differences in lipid levels between the
premenopausal cancer versus non-cancer patients
were not as marked as those between the
corresponding postmenopausal groups.
With the exception of HDL-cholesterol, the
concentrations of plasma lipids in the post-
menopausal cancer patients were significantly
higher than in the premenopausal cancer patients
(P<0.001). Non-cancerous postmenopausal patients
had higher levels of total cholesterol (P<0.05)
and triglycerides (P<0.01) than premenopausal
non-cancer patients but there were no differences
in any other plasma lipid concentrations between
these groups.
From Table IV it can be seen that concentrations
of prolactin in the plasma of cancer patients were
significantly higher than those in non-cancer
patients (P<0.01). This difference was largely due
to the marked difference in prolactin levels between
premenopausal cancer and non-cancer patients
(P<0.01). Although mean values for prolactin were
higher in cancer than non-cancer patients in the
postmenopausal group, this difference was not
statisticallysignificant(P<0.1).Itshouldbenotedthat
threepatients inthepremenopausal non-cancergroup
had fasting plasma prolactin values markedly higher
than the remainder of the group (1,549, 1,229 and
1,145punitml- 1); the diagnoses in these
patients were interlobular sclerosis (2) and duct
cyst (1).
Further analysis of prolactin values from cancer
patients divided according to histopathological
features (Table V) showed that prolactin values
weremarkedly higherin premenopausal patients with
invasive or poorly differentiated tumours (P<0.001)
compared to non-invasive premenopausal). All
patients in this group had fasting plasma pro-
lactin levels exceeding 1,000punitsml- 1. One
patient had a value of 5,525punitsml-1. In the
postmenopausal patients there was no evidence of
higher plasma ptolactin values in patients with
invasive or poorly differentiated disease and no
patients in this group showed plasma prolactin
levels greater than 1,000,uunitsml 1.
Regression analysis of body weight, plasma lipids
and plasma prolactin showed no correlations in any
of the groups, nor for the group as a whole.
Discussion
This study has demonstrated a marked elevation of
plasma lipid concentrations in all breast cancer
patients and higher plasma prolactin concentrations
in premenopausal cancer patients compared with
patients with benign disease. The finding of higher
lipid levels in these women diagnosed at an early
stage of their disease, is in agreement with the
findings of Basu and Williams (1975) who reported442 I.A. BANI et al.
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Table IV Plasma prolactin concentrations in patients
with breast cancer and those with non-cancerous breast
disease. Values are means +s.e. Number of patients is
shown in parenthesis.
Prolactin /t unitsml- 1
Pre- Post-
meno- meno-
All pausal pausal
Descriptions patients patients patients
Breast cancer 792+171 1112+278 366+51
(43) (25) (18)
Non-cancerous 342+55 409+81 240+60
breast disease (42) (22) (20)
Differences between cancer and non-cancer patients
P<0.01. Differences between premenopausal cancer and
non-cancer patients P<0.01; Differences between post-
menopausal cancer and non-cancer P<0.1; Differences
between premenopausal and postmenopausal cancer
patients P<0.01; Differences between premenopausal and
postmenopausal non-cancer patients P<0.1.
Table V Plasma prolactin concentrations in relation to
histopathology in patients with breast cancer. Values are
means+s.e. Number ofpatients is shown in parenthesis.
Prolactin p units ml-1
Premenopausal Postmenopausal
Non-invasive and
well differentiated
tumours 218+34 (12) 409+85 (10)
Invasive and poorly
differentiated
tumours 2008 +430 (12)' 338+90 (8)
aValues significantly different from premenopausal non-
invasive cases P<0.001.
elevated concentrations of plasma total lipids,
phospholipids and cholesterol in patients with
advanced disease. Concentrations of plasma fatty
acids were also significantly higher in breast cancer
patients in the present study, a, finding in agreement
with the findings of Feldman & Carter (1971) in an
investigation of postmenopausal breast cancer
patients. However in the latter study, in contrast to
the present one, plasma cholesterol levels were
reported to be lower in the cancer group. However,
Feldman & Carter carried out their investigations
on patients following surgical removal of tumours.
Previous studies have shown significant changes in
blood lipid patterns in many patients following
surgery, as part of the neuroendocrine and
metabolic response to trauma (McNamara et al.,
1972). In the present study all blood measurements
were made pre-operatively; any differences found
cannot therefore be attributed to the effects of
surgery, anaesthesia, drugs or recovery. In addition,
none of the patients were started on chemotherapy
prior to surgery. The results obtained for plasma
lipid levels therefore clearly reflect differences
associated with the disease itself, or with risk
factors related to the likely development of the
disease. Dietary factors have been strongly
implicated in the aetiology of breast cancer, as
epidemiological studies have shown an association
between dietary fat intake and disease incidence
(Wynder, 1960; Doll et al., 1970; Carroll, 1975) and
animal studies (Carroll, 1975; Carroll & Khor,
1975; Chan & Dao, 1981) strongly support such as
relationship. In postmenopausal women, overweight
has been linked to a greater risk of breast cancer
(Wynder, 1960) and there is a poorer prognosis
in pre- and postmenopausal overweight
women who develop the disease (Boyd et al., 1981;
Tarrler et at., 1981; Greenberg et al., 1985). More
recently Lubin et al. (1985) have demonstrated
a greater risk of breast cancer in women
showing greater weight gain in adult life and
Gregorio et al. (1985) have shown a poorer
outcome for women with advanced disease shown
to have a higher fat intake at time of diagnosis.
Although the relationship between diet and plasma
lipid levels is a complex one, it has been clearly
demonstrated that diets containing greater amounts
of saturated fats promote higher plasma lipid levels,
particularly cholesterol. The observation of higher
plasma lipid levels in pre- and postmenopausal
breast cancer patients in the present study, and the
more exaggerated difference observed in the
postmenopausal group may therefore be considered
to provide some support for an involvement of
dietary factors, particularly dietary fat, in the
aetiology of this disorder. Support for such a
proposition is provided from observations made in
two prospective population studies of coronary
heart disease and diet. In a study of a population in
Iowa (Wallace et al., 1982), women who
subsequently developed breast cancer were shown
to have had a higher plasma cholesterol level on
entry to the study. An earlier study in Japan,
Namura et al. (1978) fortuitously showed a higher
incidence of breast cancer in women married to
men who showed higher fat intakes. These studies
suggest that elevated lipid levels preceed the
development of the disease and may therefore be of
aetiological or predictive significance. It should be
stated however, that elevated lipid levels may not
be the result of dietary influences but may reflect
some underlying metabolic disturbance associated444 I.A. BANI et al.
directly with the disease or with some hormonal
factor related to the disease. A recent study of
membrane fatty acid composition in red cells
obtained from patients with different types of
cancer, including breast cancer, showed major
differences in fatty acid profiles in the cancer group
(Wood et al., 1985). It was suggested that such
differences may reflect a fundamental defect in lipid
metabolism associated with certain types of cancer.
Hypertriglycaemia has been observed in other types
of cancer, for example in haematological cancers
(Spiegel et al., 1982) and in lung, rectal and
stomach tumours (Dilman et al., 1981). This might
be caused by an abnormality of either lecithin
cholesterol acyltransferase (LCAT) or lipoprotein
lipase as proposed by Spiegal et al. (1982). It is of
interest that the factor 'cachectin' which is
produced by macrophages,' which has been
implicated in the cachexia associated with
neoplastic disease, also completely suppresses
lipoprotein lipase activity in isolated adipocytes
(Beutler & Cerami, 1986). It is not possible to
ascertain from the present study whether the
different lipid profiles in the breast cancer group
reflect different dietary or other risk factors or
whether these are a manifestation of the disease
itself. Clearly this area warrants further
investigation. In particular it would be valuable to
assess the possible efficacy of dietary measures in
returning plasma lipid profiles to normal in breast
cancer patients. Investigations of plasma lipid levels
may also be of value in screening women for breast
cancer risk.
The results obtained for plasma prolactin
concentrations in the present investigation support
these of Malarkey' et al. (1977) in that higher levels
were observed in pre- but not postmenopausal
breast cancer patients. Although stress has been
reported to be a major factor in stimulating
prolactin release (Noel et al., 1972) it is unlikely
that differences in stress are the cause of the results
reported here. None of the patients knew of their
diagnosis prior to surgery, confirmation of
malignant disease only being made following
removal of the tumour. If greater stress due to
suspicion of a more unfavourable outcome existed
in the cancer patients, then higher prolactin levels
would also have been exhibited in the post-
menopausal group. In these patients, however,
prolactin values were similar to those in the control
group. Studies in animals suggest that prolactin
may have potent and complex effects on lipid
metabolism. In particular prolactin is reported to
increase glucose uptake and fatty acid synthesis in
adipose tissue (Hamid, et al., 1965) and lipogenesis
in liver (MacLeod et al., 1968). Prolactin is also
reported to cause accelerated lipid hydrolysis in
adipose tissue (Hamid et al., 1965) and raises fatty
acid levels in children (Elsair & Denine, 1970).
From such observations it is tempting to speculate
that disturbances in lipid metabolism in breast
cancer may be related to elevations of prolactin, or
indeed that dietary induced changes in prolactin
secretion may provide the mechanism by which
plasma lipid alterations occur in this disease. Such
a proposition is made unlikely by the observation
of higher prolactin levels in premenopausal cancer
patients in whom disturbances in lipid levels are
less marked than in postmenopausal patients. In
addition no correlations were observed between
individual plasma prolactin and lipid values in any
of the groups, nor in the patients as a whole.
Furthermore, the observation of particularly high
prolactin levels in patients with invasive or poorly
differentiated disease, suggests that elevation of this
hormone operates independently of dietary or
metabolic factors. Whether the higher prolactin
levels are the result of more extensive disease, or
reflect a stimulative effect of prolactin on the
disease is unclear. Why such differences were not
observed in patients in the postmenopausal group is
also unclear. In view of the differences which are
believed to exist between pre- and postmenopausal
cancer (DeWaard, 1979) this observation requires
further investigation.
The authors are grateful to the patients for their
willingness to participate in this study and to Dr. Lyndon
Jones for his helpful advice. I.A.B. was in receipt of a
Government Scholarship from the Sudan.
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